Previous 10 | Next 10 |
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) ...
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President ...
2023-05-15 17:32:24 ET Vaccinex press release ( NASDAQ: VCNX ): Q1 GAAP EPS of -$0.10. Revenue of $0.55M. For further details see: Vaccinex GAAP EPS of -$0.10, revenue of $0.55M
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneeri...
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated ...
GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New technology makes it possible to present GPCR and ion channels i...
2023-04-03 08:58:27 ET Vaccinex ( NASDAQ: VCNX ) closed the private placement of 4.98M shares at a purchase price of $0.41/share for gross proceeds of $2.04M. Net proceeds from the private placement to be used for funding the ongoing development and clinical trials of its...
2023-04-03 08:40:11 ET Vaccinex press release ( NASDAQ: VCNX ): FY GAAP EPS of -$0.47. Revenue of $0.28M (-68.9% Y/Y). For further details see: Vaccinex GAAP EPS of -$0.47, revenue of $0.28M
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4...
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a pre-planned interim analysis of KEYNOTE B84 phase 1b/2 study in Head and Neck Squam...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...